Use of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 [TIMP2]•[IGFBP7] as an AKI risk screening tool to manage patients in the real-world setting

Sandra L. Kane‐Gill, Sadudee Peerapornratana, Adrian Wong, Raghavan Murugan, Lara Groetzinger, Catherine Kim, Pamela L. Smithburger, Janine Then, John A. Kellum